Merck presents at ASCO inferior results than ONCS has achieved and the stock immediately has movement. ONCS will rise considerably as trial results continue to come in with high efficacy numbers. ONCS strong buy.
Sentiment: Strong Buy
finally, a good post
Yup, ONCS proving stronger than competitors like BMY and MRK.
ONCS results better, keep fighting cancer